The oncoprotein KRAS was for decades considered an “undruggable” target, and recently, sotorasib (AMG510) was approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with specific KRAS G12C-mutated locally advanced or metastatic NSCLC [19]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.